GlobeNewswire

Equillium to Participate in Upcoming Investor Conferences
05/11/2026
LA JOLLA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today announced that [...]
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
05/11/2026
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or [...]
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
05/11/2026
Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion Using TAMP [...]
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/11/2026
NEEDHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Sight Sciences to Present at Two Upcoming Investor Conferences
05/11/2026
MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
The Joint Corp. Reports Third Quarter 2026 Financial Results
05/11/2026
- Revenue Increases to $13.6 Million - - Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Million - - [...]
AVITA Medical Reports Third Quarter Results
05/11/2026
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic [...]
Vaxart Provides Business Update and Reports Third Quarter 2026 Financial Results
05/11/2026
Topline data from 400-person sentinel safety cohort and approximately 5,000 patients in main cohort Phase 2b COVID-19 trial anticipated by mid-year 2027 Expanded intellectual property portfolio with new European patent [...]
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
05/11/2026
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation [...]
LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
05/11/2026
Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of LB [...]
CVRx Reports Third Quarter 2026 Financial and Operating Results
05/11/2026
MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
SkinHealth Systems Reports Third Quarter 2026 Financial Results
05/11/2026
LONG BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial®, today announced financial results for the third [...]
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
05/11/2026
REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by [...]
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
05/11/2026
Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and [...]
ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
05/11/2026
SAN CLEMENTE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
FocalTherics™ Reports Third Quarter 2026 Financial Results
05/11/2026
45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, [...]
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
05/11/2026
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal [...]
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/11/2026
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Troisième Trimestre 2026
05/11/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Troisième Trimestre 2026 Le chiffre d’affaires net mondial s’est élevé à 9,2 millions d’euros, porté par une croissance séquentielle [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum